The overall goal of the NCTN Program is to """"""""conduct definitive, randomized, late phase clinical treatment trials and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials, as part of the NCI's overall clinical research program for adults and children with cancer."""""""" The mission of the NCIC CTG is """"""""to develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease."""""""" The overlaps of these goals create a rationale for a Canadian Collaborating Clinical Trials Network. This rationale is further supported by similar societal expectations by Canadians and Americans for improved health outcomes and similar respective strategic priorities of NCIC CTG and the NCTN that recognize that new understandings of the molecular basis of carcinogenesis have the potential to advance health care delivery, including through improved therapeutic targeting of the cancer cell and better identification of therapies for individual patients. The specific objectives of NCIC CTG to collaborate with NCI/CTEP and US-based groups, through its newly-formed National Clinical Trials Network Program, to develop new Intergroup trials under NCIC CTG leadership and to ensure more rapid accrual to trials led by US-based groups, to enhance the scientific content of these trials through evaluation of additional endpoints and to contribute to new understandings of clinical trial methodology and analysis.
This aim i s facilitated by NCIC CTG's unique information technology supports and understandings of the Canadian regulatory environment.
The aims of this application are to facilitate Canadian leadership of NCTN trials that represent value from the perspective of expenditure of U.S. federal dollars and to conduct U.S.-led NCTN trials in Canada.
The NCIC CTG is the only adult cooperative oncology group based in Canada that has a national membership and is committed to assessing all modalities of therapy across the spectrum of different types of cancer. The Group's activities have included leadership of and participation in large randomized phase clinical trials conducted in the US and Canada by both the NCIC CTG and US-based cooperative groups.
|Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91|
|Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19|
|Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16|
|Haas, Naomi B; Manola, Judith; Ky, Bonnie et al. (2015) Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res 21:4048-54|
|Seymour, Lesley; Groshen, Susan; Rosner, Gary L et al. (2015) Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res 21:5057-63|